News
Almost one third of life science companies set to begin quantum computing evaluation this year
New survey results from the Pistoia Alliance, the Quantum Economic Development Consortium (QED-C) and QuPharm show almost one third (31 percent) of life science...
Clinical Trials
Byondis Investigational Antibody-Drug Conjugate SYD985 Selected for I-SPY 2 TRIAL in Early-Stage Breast Cancer
Byondis B.V. announced that Quantum Leap Healthcare Collaborative selected the company’s investigational antibody-drug conjugate (ADC) SYD985 (trastuzumab duocarmazine) for a new investigational treatment arm...
News
Tim Consult launches air cargo benchmarking initiative for pharma industry
Air freight experts at Tim Consult have launched the special Market Intelligence Initiative “MII Pharma Air Cargo”, aimed at providing pharmaceutical industry specialists with...
News
Arctoris contributes its capabilities and expertise to the fight against COVID-19
Arctoris Ltd. supports global research efforts to find new therapeutics against COVID-19.
Scientists in academic centres and companies around the world desperately search for novel...
Articles
U.S. Biomedical Innovation needs the Human Touch
Never has the spotlight shone brighter on the pharmaceutical industry. With the coronavirus continuing to claim lives across America, the stakes are high for...
Clinical Trials
Pfizer and BioNTech Granted FDA Fast Track Designation for Two Investigational mRNA-based Vaccine Candidates Against SARS-CoV-2
Pfizer Inc. and BioNTech SE announced that two of the companies’ four investigational vaccine candidates from their BNT162 mRNA-based vaccine program (BNT162b1 and BNT162b2)...
Press Releases
Biocon’s Breakthrough Drug Itolizumab Receives DCGI Nod for its Use in Moderate to Severe COVID-19 Patients
Biocon Ltd., an innovation-led global biopharmaceuticals company, announced that it has received the Drugs Controller General of India’s (DCGI) approval to market Itolizumab (ALZUMAb®)...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read